Mini Samples ELISA Kit for Fibroblast Growth Factor 23 (FGF23)

ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor

Specificity

This assay has high sensitivity and excellent specificity for detection of Mini Samples Fibroblast Growth Factor 23 (FGF23).
No significant cross-reactivity or interference between Mini Samples Fibroblast Growth Factor 23 (FGF23) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Mini Samples Fibroblast Growth Factor 23 (FGF23) and the recovery rates were calculated by comparing the measured value to the expected amount of Mini Samples Fibroblast Growth Factor 23 (FGF23) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 84-104 95
EDTA plasma(n=5) 88-95 91
heparin plasma(n=5) 82-98 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Mini Samples Fibroblast Growth Factor 23 (FGF23) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Mini Samples Fibroblast Growth Factor 23 (FGF23) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Mini Samples Fibroblast Growth Factor 23 (FGF23) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-97% 78-93% 84-102% 83-97%
EDTA plasma(n=5) 89-96% 95-104% 94-101% 85-98%
heparin plasma(n=5) 84-101% 80-92% 89-96% 78-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×60µL Assay Diluent A 1×6mL
Detection Reagent B 1×60µL Assay Diluent B 1×6mL
TMB Substrate 1×4.5mL Stop Solution 1×3mL
Wash Buffer (30 × concentrate) 1×10mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 25µL standard or sample to each well. Incubate 1 hour at 37°C;
3. Aspirate and add 25µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 25µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 25µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 20µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Journal of international medicine Prognostic impact of renal function in precapillary pulmonary hypertension Pubmed: 24011362
BMC Nephrology FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients Pubmed: 24180481
Journal of Clinical Densitometry Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism Pubmed: 23623649
J Intern Med. Prognostic impact of renal function in precapillary pulmonary hypertension. Pubmed:24011362
Journal of Bone and Mineral Research Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth Pubmed:25639729
Nefrologia Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina PubMed: 26394828
Medicine (Baltimore) An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer PubMed: 26266370
Ann Biol Clin (Paris) Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique? PubMed: 26069069
Scandinavian Journal of Gastroenterology High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23 Pubmed:27326766
PLOS ONE Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model ofDistal Nephron Salt Wasting. pubmed:27442254
Journal of Laboratory Diagnostics Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation publication:312592751
Journal of Integrative Nephrology & Andrology Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients issn:2394-2916
Journal of Renal Nutrition ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. pubmed:29056164
Experimental Biology and Medicine(Maywood) Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats Pubmed:29763365
Psychiatry Research Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity Pubmed:29677623
BMC Pediatrics Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children Pubmed:29907141
Medical Science Monitor Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study Pubmed:29608553
International Journal of Chronic Obstructive Pulmonary Disease Disconnection of pulmonary and systemic arterial stiffness in COPD Pubmed:29881265
Saudi journal of kidney diseases and transplantation Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients Pubmed:29970732
Nephrology Dialysis Transplantation High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease Pubmed: 30189026
BioFactors  Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma Pubmed: 30334297
Biological Trace Element Research Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients Pubmed: 30847765
Clin Implant Dent Relat Res. Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases Pubmed: 31407857
JACC-Cardiovascular Imaging PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS Pubmed: 28797410
Saudi J Kidney Dis Transpl Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease Pubmed: 31696838
Biomedicine & Pharmacotherapy MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 Pubmed: 31918268
Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?
THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS
THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ¡­
Calcif Tissue Int The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations Pubmed:35665817
European Journal of Medical Genetics Genetic and clinical profile of patients with hypophosphatemic rickets Pubmed:35738466
African Health Sciences Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA746Hu01 Recombinant Fibroblast Growth Factor 23 (FGF23) Positive Control; Immunogen; SDS-PAGE; WB.
RPA746Hu02 Recombinant Fibroblast Growth Factor 23 (FGF23) Positive Control; Immunogen; SDS-PAGE; WB.
RPA746Hu03 Recombinant Fibroblast Growth Factor 23 (FGF23) Positive Control; Immunogen; SDS-PAGE; WB.
APA746Hu03 Active Fibroblast Growth Factor 23 (FGF23) Cell culture; Activity Assays.
RPA746Hu04 Recombinant Fibroblast Growth Factor 23 (FGF23) Positive Control; Immunogen; SDS-PAGE; WB.
APA746Hu01 Active Fibroblast Growth Factor 23 (FGF23) Cell culture; Activity Assays.
PAA746Hu02 Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB,IHC.
PAA746Hu03 Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC; IP.
PAA746Hu04 Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC; IP.
PAA746Hu01 Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC; IP.
LAA746Hu71 Biotin-Linked Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC.
RAA746Hu21 Recombinant Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IF; ICC; IHC; IP; FCM.
MAA746Hu23 Monoclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC; IP.
MAA746Hu22 Monoclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC; IP.
MAA746Hu21 Monoclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC; IP.
LAA746Hu72 Biotin-Linked Monoclonal Antibody to Fibroblast Growth Factor 23 (FGF23) WB; IHC; ICC.
MEA746Hu Mini Samples ELISA Kit for Fibroblast Growth Factor 23 (FGF23) Enzyme-linked immunosorbent assay for Antigen Detection.
SEA746Hu ELISA Kit for Fibroblast Growth Factor 23 (FGF23) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA746Hu Multiplex Assay Kit for Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.